Yesterday, 29 April 2015, Follicum AB held their Annual General Meeting. The meeting resolved to adopt the presented income statement and balance sheet as well as to dispose of the company’s profit according to the Board’s proposal in the Annual Report. Furthermore, the meeting decided that no dividend will be paid for fiscal year 2014. […]
Follicum’s Annual Report for the financial year 2014 is now published in Swedish on the company’s website (Swedish version). It is also available in Follicum’s office at Scheelevägen 22, Lund. For more information please contact: Dr Jan Alenfall, CEO Follicum AB Tel +46 46 19 21 97 Email firstname.lastname@example.org
Follicum AB’s Annual General Meeting will take place on April 29 2015 at 16.00 at Scheelevägen 22 in Lund. The meeting will be held in Swedish. Click here to open the document Kallelse till årsmöte (in Swedish).
Follicum announced in February 2015 that they had finished two smaller toxicity studies with favorable results. The company has now started two larger toxicity studies which will finish in August 2015. These toxicity studies are necessary to get the authorities’ approval for clinical studies. For more information please contact Dr Jan Alenfall – CEO, Follicum […]
Follicum has now finished an important preclinical study on human scalp skin biopsies which have been transplanted to SCID-mice (mice with compromised immunological defence where human skin can survive and grow). The results are all in line with the findings which previously have been communicated after short-term in vitro studies on parts of human skin performed by […]
The year-end report for the period 1 January to 31 December 2014 is now published in Swedish. To access the report please click here or visit our Swedish site by clicking the flag.
Follicum plans to start clinical studies during 2015. To be able to obtain the authorities’ approval for the clinical studies Follicum needs to present the results of preclinical studies, e g tox studies. In December 2014 Follicum started two smaller tox studies, which now are completed. The results are positive, showing that FOL-005 does not […]
Draft document prepared with a proposed design for the Phase I/II a-study to be used in the discussions with a medical agency. Two small toxicological studies have also been initiated.
Repeated experiment confirms positive results from ex vivo test on human skin tissue. The experiment was performed by a well-known research group in Münster, Germany.
Report for Q3 published (in Swedish). To open the document, click here.